Abstract
Objective: Research of clinical features in diabetic retinopathy. Evaluation of treatment outcomes diabetic retinopathy by intravitreal Bevacizumab. Patients and methods: A descriptive prospective clinical intervention non-comparative study on 33 eyes of 17 patients diabetic retinopathy who were treated by intravitreal Bevacizumab from 3/2014 to 6/2015. Results: Average age: 60.06 ± 13.108 years. Average diabetic duration: 6.145 ± 10.47 years. Average HbA1c: 9.506 ± 3.298%. The average of vision after treatment 3 month, 6 month is greater than before the treatment. The average of central retinal thickness after treatment is lowest at 3 months, then back up again at the 5th, 6th. There is no correlation between visual acuity and retinal thickness measured by OCT center before treatment, after treatment. Conclusion: Intravitreal Bevacizumab in treatment of diabetic retinopathy improve vision and macular edema after 3 months and gradually stabilize in the following months. Key words: intravitreal Bevacizumab, diabetic retinopathy
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
